Key highlights

  • Xero (ASX:XRO) closed at $75.17, up 6.08%, on the day it reported H1 FY27 results and approved an A$1 billion buy-back.
  • AUB Group (ASX:AUB) closed at $32.04, up 5.05%, following FY26 underlying NPAT of $224.6 million and FY27 guidance.
  • Imricor (ASX:IMR) closed at $1.33, up 4.72%, after the FDA completed review of its third PMA module with one deficiency.

Xero Limited (ASX:XRO), AUB Group Limited (ASX:AUB) and Imricor Medical Systems Inc (ASX:IMR) all finished higher on 12 November 2026, with Xero up 6.08%, AUB up 5.05% and Imricor up 4.72%. The S&P/ASX 200 closed at 9,146.80, down 0.07%, which suggests the gains were stock-specific rather than driven by the index.

Xero (ASX:XRO): $75.17, up 6.08%

Xero reported H1 FY27 Operating Revenue up 46% to $1.7 billion and added 226,000 net new customers to reach 5.1 million. Adjusted EBITDA rose 3% to $362 million, while statutory net profit fell to $18.5 million as Melio was consolidated for a full six months. The company lifted FY27 revenue guidance to $3.77–3.83 billion and adjusted EBITDA guidance to $880–920 million. It also approved a buy-back of up to A$1 billion over the next 12 months, to start on or after 13 November 2026.

AUB Group (ASX:AUB): $32.04, up 5.05%

AUB reported FY26 underlying NPAT of $224.6 million, up from $200.2 million, with underlying EPS of 183.69 cents. Reported NPAT fell to $96.0 million. The final Dividend was 71.0 cents, taking the FY26 total to 98.0 cents. International profit before tax rose 19.6% to $124.5 million, while Australian Broking rose 10.0% to $149.1 million. FY27 underlying NPAT guidance is $245–265 million.

Imricor (ASX:IMR): $1.33, up 4.72%

Imricor said in an announcement dated 8 October 2026 that the FDA completed its review of the third PMA module, which covers bench testing for the Vision-MR Ablation Catheter 2.0, RF-5000 System and irrigation tubing set. The review identified no deficiencies for the catheter or tubing and one deficiency for the RF-5000 generator software operating system, which the company has already updated. The fourth module is targeted for submission in November 2026.

Closing thoughts

The three companies span software, insurance broking and medical devices, and their share moves reflected company-specific news rather than a common theme. Each announcement carried a different date, which the articles above set out separately.